ADMA is an eNOS inhibitor whose levels rise in a number of pathological conditions associated with endothelial dysfunction, including diabetes, dyslipidemia and obesity [9,10]. Here, NOS3 is linked to obesity due to melanocortin 4 receptor deficiency.